Multiple Sclerosis | TreatmentTrends | US | Q3 2015
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg 3TW, oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision-making and treatment choice in the management of multiple sclerosis (MS) in the United States. Glatopa (glatiramer acetate 20 mg), the first generic DMT, entered the U.S. market in June 2015. Further, recent cases of progressive multifocal leukoencephalopathy (PML) in Gilenya- and Tecfidera-treated patients have changed the way neurologists approach treatment with these DMTs and prescribing decisions following anti-John Cunningham (JC) virus antibody assay results. TreatmentTrends: Multiple Sclerosis (US) is an annual syndicated report that provides a comprehensive view of the current and anticipated market dynamics and competitive landscape through comprehensive primary research with U.S. neurologists. These reports cover the use of DMTs for the treatment of MS as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, promotional messaging, and anticipated use. In addition, respondents are queried about their awareness of and interest in DMTs in development.